Inspire Medical Systems, INC

Inspire Medical Systems reported Q2 2026 results, with revenue down 7.6% year-over-year to $200.6 million, but raised its full-year 2026 revenue outlook and announced a strategic growth plan to generate $30 million for new initiatives.

Inspire Medical Systems, Inc. announced the immediate appointment of Michael H. Carrel to its Board of Directors, effective July 20, 2026.

Inspire Medical Systems announced the retirement of Board member Casey M. Tansey, effective July 30, 2026, after over eighteen years of service.

Inspire Medical Systems provided a comprehensive update on coding, clinical outcomes, and cardiovascular health benefits for its Inspire V therapy at the 2026 Wells Fargo MedTech Innovation Spotlight.

Inspire Medical Systems stockholders approved amendments to the incentive award plan and a declassification of the board at the April 30, 2026 annual meeting.

Inspire Medical Systems reported Q1 2026 results with a modest 1.6% revenue increase to $204.6 million, impacted by coding and reimbursement uncertainty, while revising full-year guidance downwards.

Inspire Medical Systems announced Q2 2026 results showing a revenue decrease driven by U.S. market challenges, while also detailing ongoing legal proceedings and a new strategic growth plan.

Inspire Medical Systems reported a 1.6% revenue increase for Q1 2026, but a significant net loss driven by tax impacts and operational expenses.

Inspire Medical Systems reported a 46.3% drop in Q3 net income to $9.9 million despite a 10.5% revenue increase, as new product launch delays and GLP-1 drug impacts weigh on performance.

Inspire Medical Systems reported a net loss in Q2 2025, despite revenue growth, as increased operating expenses and new product transition challenges impacted profitability.

Inspire Medical Systems reports a 22.7% increase in revenue for Q1 2025, reaching $201.3 million, and achieves net income of $3.0 million.

Inspire Medical Systems reported a significant increase in revenue and a return to profitability in the third quarter of 2024, driven by strong sales growth in the U.S. and international markets.

Inspire Medical Systems achieves its first profitable year in 2024, driven by increased adoption of its Inspire therapy for obstructive sleep apnea.

Inspire Medical Systems, a medical technology company focused on minimally invasive solutions for obstructive sleep apnea, reported its full-year 2023 results, highlighting significant revenue growth and expanding market penetration, but also noting potential headwinds.

Michael H Carrel, a Director of Inspire Medical Systems, Inc., received 5,631 shares of common stock on July 20, 2026.

Georgia Melenikiotou, a Director of Inspire Medical Systems, Inc., received 344 shares of common stock on July 15, 2026.

Casey M Tansey, a Director of Inspire Medical Systems, Inc., received 346 shares of common stock on July 15, 2026.

Gary Lee Ellis, a Director of Inspire Medical Systems, Inc., received 581 shares of common stock on July 15, 2026.

Shelley G Broader, a Director of Inspire Medical Systems, Inc., received 383 shares of common stock on July 15, 2026.

Chief Product and Innovation Officer John Rondoni sold 700 shares of Inspire Medical Systems common stock.

Inspire Medical Systems, Inc. announces robust 2025 financial and operational growth, including $912 million in revenue and over 125,000 patients treated, alongside proposals for board declassification and an equity plan amendment.

Inspire Medical Systems, Inc. has filed a definitive proxy statement with the SEC.

Inspire Medical Systems announces a profitable 2024, FDA approval for its Inspire V system, and changes to its Board and executive management.

Inspire Medical Systems, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Inspire Medical Systems' proxy statement details the agenda for the 2024 annual meeting, including director elections, auditor ratification, executive compensation approval, and board leadership transition.

Vanguard Portfolio Management has reported a beneficial ownership of 7.37% in Inspire Medical Systems Inc., holding over 2.1 million shares.

D. E. Shaw & Co., L.P. and David E. Shaw have jointly filed a Schedule 13G, reporting beneficial ownership of 5.1% of Inspire Medical Systems, Inc. common stock.

Soleus Capital has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Inspire Medical Systems, Inc.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 8.8% of Inspire Medical Systems, Inc. common stock as of March 31, 2026.

Deerfield Management and James E. Flynn have filed an amendment to their Schedule 13G, disclosing that their beneficial ownership in Inspire Medical Systems, Inc. has fallen below the 5% threshold.

Vanguard Capital Management reports beneficial ownership of 1,469,703 shares, representing 5.1% of Inspire Medical Systems' common stock as of March 31, 2026.